Tenet Healthcare Co. (NYSE:THC – Get Free Report) Director Meghan Fitzgerald sold 20,000 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $146.34, for a total transaction of $2,926,800.00. Following the sale, the director now directly owns 15,269 shares of the company’s stock, valued at approximately $2,234,465.46. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Tenet Healthcare Stock Performance
Shares of NYSE THC opened at $150.06 on Friday. Tenet Healthcare Co. has a 1 year low of $51.04 and a 1 year high of $155.00. The company has a debt-to-equity ratio of 2.53, a quick ratio of 1.38 and a current ratio of 1.45. The stock has a fifty day moving average price of $138.28 and a two-hundred day moving average price of $115.64. The firm has a market cap of $14.66 billion, a P/E ratio of 5.82, a PEG ratio of 0.76 and a beta of 2.15.
Tenet Healthcare declared that its board has initiated a share repurchase program on Wednesday, July 24th that permits the company to buyback $1.50 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 10.3% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
Institutional Investors Weigh In On Tenet Healthcare
Analyst Ratings Changes
Several equities analysts have recently commented on THC shares. The Goldman Sachs Group upped their target price on Tenet Healthcare from $156.00 to $173.00 and gave the company a “buy” rating in a report on Tuesday, July 30th. StockNews.com raised Tenet Healthcare from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 7th. UBS Group boosted their price target on shares of Tenet Healthcare from $137.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Baird R W upgraded shares of Tenet Healthcare to a “strong-buy” rating in a research report on Thursday, May 30th. Finally, Cantor Fitzgerald upped their target price on shares of Tenet Healthcare from $112.00 to $168.00 and gave the stock an “overweight” rating in a research report on Thursday, July 25th. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $149.75.
Check Out Our Latest Report on Tenet Healthcare
About Tenet Healthcare
Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.
See Also
- Five stocks we like better than Tenet Healthcare
- The 3 Best Retail Stocks to Shop for in August
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- What is the Dow Jones Industrial Average (DJIA)?
- MarketBeat Week in Review – 8/5 – 8/9
- Financial Services Stocks Investing
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Tenet Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenet Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.